She said that Express Scripts provided the FTC will more than 3.3 million pages of documents and 11 billion observable data points, but "all of it was ignored." ...

Express Scripts, one of the country’s largest pharmacy benefit managers, sued the Federal Trade Commission (FTC) Tuesday and demanded the agency retract a report saying the industry middlemen ...

Express Scripts, which Cigna acquired for $67 billion six years ago, brought in $26.6 billion in revenue in the second quarter — 44% of Cigna’s entire topline.

Express Scripts, one of the largest pharmacy benefit managers in the U.S., filed a lawsuit demanding that a recent FTC report on industry middlemen be vacated.

Express Scripts sues FTC over drug pricing report. By Jody Godoy. September 17, 2024 1:45 PM UTC Updated September 17, 2024 Federal Trade Commission seal is seen at FTC Headquarters ...

Express Scripts, a subsidiary of The Cigna Group, has filed a federal lawsuit against the US Federal Trade Commission (FTC) over a July 2024 report claiming that the report is “false and ...

Express Scripts sued the FTC over the report on Tuesday, arguing it was defamatory and damaging to the PBM’s business. Regulators and lawmakers in Washington have been more aggressive in ...

Express Scripts accuses Khan — who is named as a defendant alongside the FTC — of making her anti-PBM bias clear before taking over as chair and of playing politics. “Under Chair Lina Khan, the PBM ...

Cigna's Express Scripts filed a lawsuit Tuesday challenging a federal report that places the blame for rising drug prices on ...

Express Scripts, a subsidiary of The Cigna Group, has filed a lawsuit against the Federal Trade Commission (FTC), demanding a retraction of a July 2024 report it claims is false, misleading, and ...

Express Scripts also notes that the FTC report has fueled other problems, including legal actions and congressional scrutiny. Congress has considered a number of PBM bills over the past two years ...

Express Scripts contends in the complaint that the FTC "followed prejudice and politics, not evidence or sound economics," and that PBMs lower drug costs for employers and other health plan sponsors.